Patient capital in an impatient world

Almost every incentive in modern finance pushes in one direction: prove it now. Prove it this quarter, this fund cycle, this board meeting. The horizon over which most capital is judged has quietly collapsed to a length far shorter than the time it actually takes to build something durable. And so a great deal of capital ends up funding things that can be proven quickly, rather than things that are worth building.

Patience is a strategy, not a virtue

It is easy to talk about patient capital as if it were a matter of temperament — a willingness to be calm while others panic. It is more useful to treat it as a strategy with a specific edge. When the rest of the market is forced to demand near-term proof, the opportunities that require time to mature are systematically underpriced. Patience is how you buy them.

This is not the same as passivity. A patient investor is often more active than an impatient one, because holding through a long build means staying close to the company, supporting it through the parts of the journey that do not show up in a quarterly number, and resisting the pressure to exit at the first moment of liquidity rather than the right one.

What a long horizon makes possible

Some of the most valuable things a business can build — trust, infrastructure, a category that did not exist before — cannot be rushed. They compound slowly and then suddenly. Capital that can wait for the second half of that curve earns most of the reward. Capital that cannot, hands it to someone else.

We structure ourselves deliberately to be able to wait: holding assets across borders and generations, and answering to a mandate measured in decades rather than fiscal years. That structure is not a constraint. It is the whole point.

In an impatient world, the scarce resource is not money. It is the willingness to be right slowly. That is the resource we try to keep.

— Koundinya Holdings